Glass Lewis also recommends that shareholders vote FOR all of Palliser's proposed board change resolutions to remove seven incumbent directors, including the Chair and CEO, and appoint in their place six independent director candidates. In its voting recommendation, Glass Lewis 1 concluded that: "Palliser has presented a convincing case for rejecting the NewMed Transaction and for support of its proposed wholesale board changes at this time." Additional key points from its recommendation include: Proposed NewMed Deal Board Reform "The resounding support for Palliser's proposals from both ISS and Glass Lewis, the two premier independent proxy advisory firms, makes clear there is a better path forward for Capricorn shareholders," commented James Smith, Chief Investment Officer at Palliser Capital.